度他雄胺与非那雄胺用于良性前列腺增生患者的药物经济学评价

The economical evaluation of dutasteride versus finasteride in patients with benign prostatic hypertrophy

目的:对度他雄胺与非那雄胺用于良性前列腺增生(BPH)患者的经济性进行药物经济学评价。方法:通过构建多状态马尔科夫模型进行研究,研究角度为患者,研究对象为BPH患者,模型周期为1年,时限为25年。使用成本-效用分析对两药经济性进行分析,并用敏感性分析验证结果的稳健性。结果:对于BPH患者,使用度他雄胺相较非那雄胺的增量成本-效用比为33 062. 61元/QALY,即每提高一个质量调整生命年需要33 062. 61元,小于我国人均GDP,可能更具经济性。敏感性分析与主分析结论相一致,主分析结果较稳健。结论:对于BPH患者,使用度他雄胺相较非那雄胺可能有更好的经济性。

Objective:To evaluate the economy of dutasteride versus finasteride in patients with benign prostatic hypertrophy(BPH).Methods:A Markov model with 1 year cycle in 25 years horizon from patients perspective with benign prostatic hypertrophy was constructed to evaluate the economy of dutasteride versus finasteride using cost-utility analysis,which was verified the uncertainty using the sensitivity analysis furtherly.Results:Dutasteride is cost-saving,given that compared to finasteride,dutasteride could improve per quality adjusted life years with 33 062.61 yuan for patients with BPH,which is less than Chinese GDP per capita,and there is no uncertainty according to the sensitivity analysis.The results of the main analysis were robust.Conclusion:Compared to finasteride,dutasteride have a better economic in patients with BPH.